Directory of Peptide API Manufacturing Plants

Founded in 2000, Suzhou Tianma Pharmaceutical Group Tianji Biopharmaceutical Co., Ltd. is a high-tech enterprise and enterprise technology center in Jiangsu Province. The company's new industrial base has been completed and put into operation in Jiangsu Changshu New Material Industrial Park. It is planned to be built according to the high standards of the pharmaceutical industry at home and abroad, and is the core carrier for the integration of polypeptide and small molecule drug research and development and commercial production. Representative peptide/polypeptide preparation products include: cortisol ® terlipressin for injection, Amgas ® octreotide acetate injection, Anqi ® carbetocin injection, lidine ® thymus method for injection, etc. The base can meet the needs of capacity upgrades and business development, and provide reliable products and professional technology solutions for domestic and foreign pharmaceutical partners. (Note: Group subordinates contain a small amount of non-pharmaceutical sectors such as hotels, etc., which have been omitted.)

Teide Pharmaceutical (Zhejiang) Co., Ltd. (stock code 03880.HK) is a contract research, development and production organization (CRDMO) specializing in polypeptides, providing full-cycle services from early discovery, pre-clinical, clinical development to commercial production. Headquartered in Hangzhou, China, it has commercial production bases and offices in China and the United States, and has been deeply engaged in the field of polypeptides for more than 20 years. Provides CRO (polypeptide new chemical molecular entity discovery synthesis) and CDMO (polypeptide CMC development and commercial production) services, and has extended to oligonucleotide CDMO since 2021. It has provided more than 1,000 customers worldwide with support for the synthesis, development, production and CMC declaration of polypeptides that meet the regulatory requirements of major markets around the world. The project covers more than 50 countries such as China, the United States, Japan, Europe, South Korea and Australia. Clients include large pharmaceutical companies, biotech companies, virtual pharmaceuticals and start-ups. The peptide biochemical tirpopeptide drug substance in the subsidiary has completed the US FDA DMF registration.

Sinopep-Allsino Biopharmaceutical is a global commercial API provider and full-service CDMO focused on end-to-end CMC development and commercial production of peptides, oligonucleotides and small molecule APIs. Serving global innovative pharmaceutical companies since 2009, it has passed four US FDA inspections and strictly follows FDA and ich guidelines. The peptide production capacity reaches 20–30 metric tons per year; a large-scale GMP oligonucleotide base has been built in Lianyungang, Jiangsu Province (annual output can reach thousands of kilograms, containing ASO, siRNA, GalNAc, AOC, liposomes and other conjugates). Services cover polypeptide/oligonucleotide CDMO, FTE, discovery services, generic APIs and preparations (oral solid preparations, lyophilized powder injections, etc.), providing process development, analytical method development and validation, stability research, and IND/NDA regulatory support to achieve a seamless connection from early development to commercial supply.

Conscientia Industrial is a core member of the Conscientia Group, headquartered in China, focusing on the R&D, manufacturing and global marketing of high-quality APIs (APIs), peptides, nutritional ingredients, cosmetic ingredients and fine chemicals. Its manufacturing facilities and products comply with international standards such as GMP and ISO, and its APIs strictly comply with USP, BP, EP, JP, KP, CP and other pharmacopoeial requirements. In the field of peptides, the company provides high-purity peptide synthesis and supply. The products cover hundreds of peptides such as α-Casozepine, AOD-9604, BPC-157, CJC-1295, GHK-Cu, GLP-1 (smectin, tilapopeptide, liraglutide, mazdopeptide, retalutide, etc.), beauty and scientific research peptides, all of which have been verified by HPLC with purity of 98% +. The supply is stable and supports rapid global shipments. It is positioned to provide peptides and raw materials for the global life science and chemical industries.

Suzhou Nike Tai Biotechnology Co., Ltd. (Suzhou) is an innovative biotechnology enterprise focusing on innovative research and development and customized production of polypeptides. Relying on advanced synthetic technology platform and strict quality management system, it provides high-purity, high-quality polypeptide raw materials and integrated solutions from milligrams to kilograms in the fields of medicine, skin care and health. The main business covers peptides/cosmetic peptides/pharmaceutical peptides: the field of peptide raw materials provides bioactive peptides (scientific research, diagnostics, pharmaceutical intermediates); cosmetic peptides focus on active peptides such as anti-aging, repair, and firming; pharmaceutical peptides focus on research and development and process development of highly difficult pharmaceutical peptides, providing innovative drug and generic drug companies with one-stop CMC services from preclinical to commercialization. Equipped with a modern R&D center and GMP-compliant production facilities, we aim to be a reliable partner in the field of peptide technology.

Sichuan Tongsheng Biomedical Co., Ltd. (founded in 2011, Deyang) is committed to providing key starting materials (KSM) and intermediates for polypeptide drugs and chemical drugs. The products cover the screening, small trials, pilot trials to commercial production services of key materials for clinical new drugs, including polypeptide drugs KSM, Fmoc-amino acids, unnatural amino acids, polypeptide side chains, short peptides, and small molecular drugs KSM, Boc-amino acids, amino acid derivatives, and heterocyclic pharmaceutical intermediates. The company has a number of 50-5000L reactor multi-functional production lines (grams to 100 tons), R&D team of 30 people (including 2 doctorate, 6 master's), QC/QA of nearly 30 people; currently planning to build about 65 acres of new base (including GMP workshop, three multi-functional workshop and peptide protection amino acid line workshop), has provided custom synthesis services for the world's leading pharmaceutical companies, CDMO and API companies.

Sichuan Pengting Technology Co., Ltd. (founded in 2021, Sichuan) is positioned as a core value creator in the global peptide industry chain, focusing on the research and development, customization and industrial-scale production of high-value APIs and cosmetic peptides. Integrated supply chain and 6,500 ㎡ co-production base, products cover metabolic APIs (Tirzepatide, Semaglutide, Retatrutide, etc.) and popular cosmetic raw materials (GHK-Cu blue copper peptide, Melanotan-II, etc.). With ISO/GMP dual certification, we can provide a full set of DMF, COA and MSDS documents. The R&D team includes 5 + PhDs, and has industrialized more than 100 effective raw materials. We support 50g trial orders to tonnage commercial supply, with a delivery period of 15–30 days. Customers cover biotechnology innovation pharmaceutical companies, CDMOs, cosmetic brands and scientific research institutions in North America, Europe and Asia.

Founded in 2018, it focuses on the European, American, Indian, and African markets, and supports Paypal, Western Union, and Bitcoin payments.

Shenzhen Jianxiang Biotechnology (JYMed/Jianyuan Pharmaceutical) is a CDMO enterprise specializing in polypeptides, providing polypeptide API R&D and GMP production from milligrams to tons. With 13 cGMP production lines and 85,000 L spps/LPPS reactor volumes, the Hubei base has an annual production capacity of 10 + tons and has passed FDA, NMPA, and EDQM inspections. Employees of 650 + are located in Shenzhen (7,000 ㎡ R&D center), Hubei (52,000 ㎡ API production base, OEB-5 isolation), and Shenzhen (formulation FDF base). Services cover custom synthesis, polypeptide API manufacturing (long chain, unnatural amino acids, conjugates), cosmetics/veterinary drugs/health peptides and CDMO, supporting 1 g R&D to 100 kg commercial batches. With 20 + years of experience in peptide chemistry and CDMO, we provide peptide intermediates, APIs and CDMO services to pharmaceutical companies worldwide.

Shenzhen Han Yu Pharmaceutical Co., Ltd. (listed on the Shenzhen Stock Exchange, 300199, listed in 2011) is a national high-tech enterprise specializing in the R&D, production and sales of polypeptide drugs and small nucleic acids. Founded in 1998, it is an early listed polypeptide drug enterprise in China. The company has built a national and local joint engineering laboratory for polypeptide drugs, a national public experimental center for innovative polypeptide drugs, and a national pilot technology platform for the preparation of polypeptide drugs. It has undertaken a number of national-level projects and won the second prize of the National Technology Invention Award. It has passed the GMP/cGMP certification in China, the United States, the European Union, Brazil, Australia, South Korea and other countries, and has four major production bases: Shenzhen Pingshan Preparation Base, Wuhan Peptide Featured API Base (through the China/United States/Australia GMP certification, which is being expanded), Gansu Chengji Pharmaceutical Intermediates Base, Yunnan Dali Industrial Hemp Base, etc., to open up the whole chain control from raw materials to drugs. The APIs are sold to 20 + countries and regions, and the preparations are sold to 90 + countries and regions. The polypeptide products include GLP-1 injections such as liraglutide, smeclutide, tirpotide, etc., atoxiban, etibapeptide, etc., and have CRDMO (custom R&D + custom production) capabilities. The monomer reactor capacity is 100L-10000L.

Shanghai Bootech Biotechnology Co., Ltd. (registered as "Bootech" on the official website, and the user is recorded as "Botech") was founded in 2003 and is a technology company specializing in the synthesis of peptides and the sale of supporting reagents. The company relies on and absorbs international advanced technology, has advanced synthesis and purification equipment, and develops a complete set of peptide synthesis routes, which can provide peptide products of various sizes and requirements (mg to kg). Each polypeptide is accompanied by HPLC analysis and mass spectrometry identification report. Provided by a number of senior researchers/professors to provide process guidance, long-term cooperation with domestic and foreign pharmaceutical companies and scientific research institutions to provide high-quality peptides and peptide raw materials products at a price advantage.

Shaanxi TNJONE Pharmaceutical Co., Ltd.) has been deeply engaged in the field of pharmaceutical raw materials for more than ten years. It is a high-tech enterprise integrating scientific research, production and sales. It has a GMP-compliant API factory in Huxian, Shaanxi. The company focuses on customized peptide and intermediate products. API meets CP, USP, BP, EP pharmacopoeial standards and supports third-party testing and certification. It is equipped with advanced analysis, concentration, purification, lyophilization and synthesis equipment. It has a professional QA/QC team and provides OEM/ODM customization services. Cumulative service 300 + customers, export 50 countries, R & D personnel 30 +. Peptide products include Tirzepatide, Retatrutide, cosmetic peptides (such as GHK-Cu, Palmitoyl Tetrapeptide-7), etc., while operating plant extracts.

Qingdao Sigma Chemical Co., Ltd.) mainly develops, manufactures and sells pharmaceutical raw materials, chemical intermediates, biochemicals, veterinary drugs and nutritional products, with synthetic capacity ranging from grams to tons, and provides custom synthesis and contract production (CMO). Peptides are one of its product lines. The official website lists GHRP-6, CJC-1295, Melanotan, HGH Frag 176-191, Ipamorelin, Hexarelin, PT-141 and other peptide raw materials, and claims to have a professional production quality control team, domestic and foreign warehousing and global shipping channels.

Founded in 2021, Motif Biotech is located in Suzhou High-tech Zone. In March 2023, the peptide R&D and production base was completed and put into production. Motif Biotech is an innovative peptide CRDMO enterprise focusing on the customization, R&D, production and service of peptide-related products. Motif Biotech is committed to becoming an international platform integrating peptide scientific research and customization, drug peptide intermediates and impurity customization, peptide API production, drug peptide R&D and process development, and beauty peptide R&D and production. The factory building of Suzhou headquarters is about 4,300 square meters, with multiple R&D and production workshops, more than 100 synthesis/purification/analysis laboratories, and a planned total annual raw material production capacity of 30 kg (powder). The GMP workshop was designed and constructed according to ich Q7, and obtained the Pharmaceutical Manufacturing License in October 2024. The production and quality meet the requirements of FDA, EMA, and NMPA. The telpopeptide API was successfully registered with the FDA in January 2025 (DMF filing). With a complex long-acting peptide modification and optimization service platform, it can produce more than 95% of customized synthetic peptide types on the market; provide full-process peptide CDMO/CMC services from drug screening (SAR), preclinical CMC, clinical samples to registration support, as well as CRO, CMO, and beauty peptide one-stop services. We have accumulated more than 35 years of industry cooperation experience, more than 1,000 cooperative customers, and 2 production bases.

Nortex Biotech (stock code 688076) focuses on polypeptide drugs and small molecule drugs, adopts the combination of independent R&D and custom R&D and production, and forms self-developed and customized two-wheel drive in the fields of advanced pharmaceutical intermediates, APIs and preparations. The company was established in Lianyungang in 2009 and listed on the Science and Technology Innovation Board in 2021. Its Hangzhou Aosino focuses on the R&D and production of new small molecule drugs, advanced intermediates and peptide fragments (Zhejiang Hangzhou R&D Center + Jiande GMP Commercialization Base). In terms of peptide APIs, there is a large production capacity of side chain chemically modified peptides and long chain modified peptides with a single batch of 10 kg or more, and the production capacity of peptide APIs has reached tonnage (expected to reach several tonnage by the end of 2025). A quality management system in line with USFDA/EDQM/NMPA has been established. The Lianyungang factory has successively passed the US FDA on-site inspection/flight inspection, South Korea MFDS, Brazil ANVISA and other inspections. The R&D team is led by experts such as the "100 Talents Program" of the Chinese Academy of Sciences, and provides CDMO/CMO services from advanced intermediates and APIs to preparations for innovative pharmaceutical companies around the world. It has R&D centers and production bases in Hangzhou/Lianyungang/Jiande and more than 2,000 employees.

Founded in 2014, Hangzhou Go Top Peptide Co., Ltd. (Go Top Peptide) is a national high-tech enterprise focusing on the R&D and production of polypeptides and related derivatives. It is the governing unit of the polypeptide branch of the China Biochemical Pharmaceutical Industry Association. The company has more than 4,000 square meters of polypeptide research and development center in Hangzhou, and has established two commercial polypeptide production bases in Shangyu and Anji, Zhejiang. It has a number of polypeptide production lines, large-scale polypeptide synthesis equipment, imported HPLC analysis and preparation equipment, and is equipped with a GMP standard clean laboratory. It has passed ISO9001: 2015 quality management system certification. Provides peptide customization, modification, catalogue peptides and scientific/pharmaceutical peptide products.

Established in 2023, Hangzhou Beiputai Biopharmaceutical Co., Ltd. is a high-tech enterprise focusing on the R&D and sales of polypeptides and related derivatives. The company has established a polypeptide R&D center in the Overseas Student Entrepreneurship Park in Qiantang District, Hangzhou. It is equipped with several polypeptide R&D production lines and large-scale analytical equipment such as Agilent high-performance liquid chromatography and AB mass spectrometry. The R&D team has more than 10 years of polypeptide experience and can meet personalized customization. Products include GLP-1 polypeptides (Smeglutide, Tirpopeptide, Retalutide, etc.), small molecule mimetic peptides, radioimaging polypeptide precursors (RDC precursors, such as FAPI/PSMA/Oct), PDC polypeptides, polypeptide inhibitors (aldehyde peptides/FMK/CMK, etc.), luciferase substrates, glycopeptides, isotope-labeled peptides, macrocyclic polypeptides, maps complex antigen peptides, fluorescent labeled peptides, cell transmembrane peptides, etc. More than 100 mature polypeptides have been produced, with an annual output of more than 100 kg of polypeptides.

Hangzhou Mandy Biotechnology Co. Founded in April 2014,, Ltd. is a Chinese peptide product R&D, production and export enterprise, focusing on independent R&D, manufacturing and customization of peptide products, with strong R&D and quality control capabilities in the biomedical industry. With more than ten years of experience in polypeptide research and development, the company has established a strict quality control system to provide polypeptide products and customized solutions to scientific research institutions, pharmaceutical companies and biotechnology companies around the world.

Seno Biotechnology is a "specialized specialty" and national high-tech enterprise focusing on the field of polypeptides. It was listed in 2021 and integrates R&D, production and sales. Its business covers polypeptide APIs, cosmetic active peptides, CDMO services and polypeptide preparations. It is a leader in the field of polypeptide APIs in China and has a full industrial chain capability from drug discovery to commercial production. The core team has more than 15 years of peptide synthesis research and practical experience. Peptide API production capacity of 1.5 tons, single batch production of up to kg, master more than 50 domestic and foreign marketed peptide production of large-scale key technologies, products covering the digestive system, immune system, anti-tumor, chronic hepatitis B, diabetes and obstetrics and other therapeutic areas, a variety of products have passed the multi-national certification.